Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram, Duloxetine, and Bupropion in Major Depressive Disorder
NCT03623711Phase 1Unknown
- Start
- Aug 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Escitalopram oxalate oral solution, duloxetine and bupropion in major depressive disorder (MDD) (4 arms). Primary endpoint: Functional Magnetic Resonance Imaging change at 12 weeks. Status: unknown.
02
Drugs
Escitalopram oxalate oral solutionduloxetinebupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03623711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623711.